Chemotherapy for Advanced or Recurrent Endometrial Cancer
Name of the Trial
Why Is This Trial Important?
Currently, there is no standard treatment for endometrial cancer that has spread beyond the uterus or recurred. Doctors treating patients with such cancers usually rely on one of two chemotherapy combinations: treatment with the drugs doxorubicin, cisplatin, and paclitaxel plus the biologic agent filgrastim (TAP) or with a combination of carboplatin and paclitaxel (TC).
In this trial, researchers will compare these two chemotherapy combinations in women with advanced or recurrent endometrial cancer to determine which combination will help patients survive longer. Additionally, the researchers will assess the patients' quality of life and examine the side effects of each combination.
"This is the most recent in a series of trials evaluating new drug treatments for endometrial cancer," said Dr. Miller. "In our previous studies, TAP emerged as the leading treatment choice. Many oncologists, however, use the TC combination, which is also used to treat ovarian cancer.
"This study is designed to set the standard of care for women with advanced endometrial cancer by comparing these two leading chemotherapy combinations," Dr. Miller said.
Who Can Join This Trial?
Where Is This Trial Taking Place?
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.